Product Description
Ono Pharmaceuticals is developing ONO-2020 (Epigenetic Regulation), an oral drug candidate currently undergoing clinical trials. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05507515?term=ONO-2020&draw=2&rank=1)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Ono Pharmaceutical Co.,LTD
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Alzheimer Disease|Dementia|Mild-Moderate Alzheimer Disease|Psychomotor Agitation|Symptoms of Alzheimer Disease
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2031240641 |
jRCT2031240641 | P2 |
Recruiting |
Dementia |
2027-03-31 |
|||
NCT06803823 |
ONO-2020-03 | P2 |
Recruiting |
Symptoms of Alzheimer Disease|Alzheimer Disease|Psychomotor Agitation |
2026-12-31 |
12% |
2025-03-29 |
Primary Endpoints |
jRCT2031240712 |
jRCT2031240712 | P2 |
Not yet recruiting |
Mild-Moderate Alzheimer Disease|Alzheimer Disease |
2026-11-30 |
63% |
||
NCT06881836 |
ONO-2020-02 | P2 |
Active, not recruiting |
Alzheimer Disease |
2026-07-31 |
63% |
2026-09-01 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
jRCT2071250125 |
jRCT2071250125 | P1 |
Not yet recruiting |
Healthy Volunteers |
2026-07-31 |
Recent News Events
Date |
Type |
Title |
|---|